A novel immune‑related lncRNA as a prognostic biomarker in HER2<sup>+</sup> breast cancer

Li,Xinwei; Meng,Yue; Gu,Bing

doi:10.3892/ol.2024.14402

A novel immune‑related lncRNA as a prognostic biomarker in HER2⁺ breast cancer

Authors:
- Xinwei Li
- Yue Meng
- Bing Gu
View Affiliations

Affiliations: Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong 510080, P.R. China, Department of Clinical Laboratory, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong 510080, P.R. China
Published online on: April 16, 2024 https://doi.org/10.3892/ol.2024.14402
Article Number: 269
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Human epidermal growth factor receptor 2 (HER2)⁺ breast cancer is characterized by high malignancy and poor prognosis. Long non‑coding (lnc)RNAs are crucial in breast cancer progression and prognosis, especially in tumor‑associated immune processes. The present study aimed to elucidate novel lncRNAs related to immune function that could serve as biomarkers for both diagnosis and prognosis of this cancer subtype. Using data from The Cancer Genome Atlas and The Immunology Database and Analysis Portal, correlation analysis was performed to identify differentially expressed lncRNAs and immune‑related genes. Through receiver operating characteristic analysis, the diagnostic value of specific lncRNAs was identified and evaluated, with a focus on their capacity to distinguish between cancerous and non‑cancerous states. The present research revealed 22 differentially expressed lncRNAs and 23 differentially expressed immune‑related genes, with 19 immune‑related lncRNAs. A total of 13 of these lncRNAs demonstrated diagnostic relevance. In particular, it was demonstrated that the expression of lncRNA CTC‑537E7.2 was significantly correlated with patient survival, suggesting its potential as a prognostic marker. Additionally, the expression of lncRNA CTC‑537E7.2 was significantly correlated with clinical parameters, such as hormone receptor status and patient demographics. Moreover, it exhibited associations with four distinct immune cell types and demonstrated involvement in the Janus kinase‑signal transducer and activator of transcription pathway. Further assessment by in situ hybridization confirmed the increased expression of lncRNA CTC‑537E7.2 in samples from HER2+ patients, reinforcing its significance. In summary, the present study uncovered a novel prognostic biomarker for HER2+ breast cancer, thereby laying the groundwork for investigating the underlying molecular mechanisms driving the development of this subtype of breast cancer.

View Figures

View References

1	Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022. View Article : Google Scholar : PubMed/NCBI
2	Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 295:2492–2502. 2006. View Article : Google Scholar : PubMed/NCBI
3	Cronin KA, Harlan LC, Dodd KW, Abrams JS and Ballard-Barbash R: Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US. Cancer Invest. 28:963–968. 2010. View Article : Google Scholar
4	Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
5	Sun M and Kraus WL: From discovery to function: The expanding roles of long noncoding RNAs in physiology and disease. Endocr Rev. 36:25–64. 2015. View Article : Google Scholar : PubMed/NCBI
6	Ao X, Ding W, Li X, Xu Q, Chen X, Zhou X, Wang J and Liu Y: Non-coding RNAs regulating mitochondrial function in cardiovascular diseases. J Mol Med (Berl). 101:501–526. 2023. View Article : Google Scholar : PubMed/NCBI
7	Chen YG, Satpathy AT and Chang HY: Gene regulation in the immune system by long noncoding RNAs. Nat Immunol. 18:962–972. 2017. View Article : Google Scholar
8	Liu Y, Ding W, Wang J, Ao X and Xue J: Non-coding RNA-mediated modulation of ferroptosis in cardiovascular diseases. Biomed Pharmacother. 164:1149932023. View Article : Google Scholar : PubMed/NCBI
9	Sun M, Gadad SS, Kim DS and Kraus WL: Discovery, annotation, and functional analysis of long noncoding RNAs controlling cell-cycle gene expression and proliferation in breast cancer cells. Mol Cell. 59:698–711. 2015. View Article : Google Scholar
10	Chen DQ, Zheng XD, Cao Y, HeX D, Nian WQ, Zeng XH and Liu XY: Long non-coding RNA LINC00628 suppresses the growth and metastasis and promotes cell apoptosis in breast cancer. Eur Rev Med Pharmacol Sci. 21:275–283. 2017.
11	Jiang X, Zhou Y, Sun AJ and Xue JL: NEAT1 contributes to breast cancer progression through modulating miR-448 and ZEB1. J Cell Physiol. 233:8558–8566. 2018. View Article : Google Scholar
12	Ahmadpour ST, Orre C, Bertevello PS, Mirebeau-Prunier D, Dumas JF and Desquiret-Dumas V: Breast cancer chemoresistance: Insights into the regulatory role of lncRNA. Int J Mol Sci. 24:158972023. View Article : Google Scholar
13	Denaro N, Merlano MC and Lo Nigro C: Long noncoding RNAs as regulators of cancer immunity. Mol Oncol. 13:61–73. 2019. View Article : Google Scholar
14	Zhang L, Xu X and Su X: Noncoding RNAs in cancer immunity: Functions, regulatory mechanisms, and clinical application. Mol Cancer. 19:482020. View Article : Google Scholar : PubMed/NCBI
15	Shen Y, Peng X and Shen C: Identification and validation of immune-related lncRNA prognostic signature for breast cancer. Genomics. 112:2640–2646. 2020. View Article : Google Scholar : PubMed/NCBI
16	Lingle W, Erickson BJ, Zuley ML, Jarosz R, Bonaccio E, Filippini J, Net JM, Levi L, Morris EA, Figler GG, et al: 2016.The Cancer Genome Atlas Breast Invasive Carcinoma Collection (TCGA-BRCA) (Version 3) [Data set]. The Cancer Imaging Archive. https://doi.org/10.7937/K9/TCIA.2016.AB2NAZRP
17	Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W and Smyth GK: limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43:e472015. View Article : Google Scholar : PubMed/NCBI
18	Hanley JA and McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 143:29–36. 1982. View Article : Google Scholar : PubMed/NCBI
19	Chen B, Khodadoust MS, Liu CL, Newman AM and Alizadeh AA: Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol. 1711:243–259. 2018. View Article : Google Scholar
20	Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
21	Matkowski R, Gisterek I, Halon A, Lacko A, Szewczyk K, Staszek U, Pudelko M, Szynglarewicz B, Szelachowska J, Zolnierek A and Kornafel J: The prognostic role of tumor-infiltrating CD4 and CD8 T lymphocytes in breast cancer. Anticancer Res. 29:2445–2451. 2009.PubMed/NCBI
22	Yeo W, Chan SL, Mo FK, Chu CM, Hui JW, Tong JH, Chan AW, Koh J, Hui EP, Loong H, et al: Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)-a correlative study to explore potential biomarkers for response. BMC Cancer. 15:3952015. View Article : Google Scholar : PubMed/NCBI
23	Azim HA Jr, Peccatori FA, Brohée S, Branstetter D, Loi S, Viale G, Piccart M, Dougall WC, Pruneri G and Sotiriou C: RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. Breast Cancer Res. 17:242015. View Article : Google Scholar : PubMed/NCBI
24	Hu W, Li X, Zhang C, Yang Y, Jiang J and Wu C: Tumor-associated macrophages in cancers. Clin Transl Oncol. 18:251–258. 2016. View Article : Google Scholar
25	Xiong S, Dong L and Cheng L: Neutrophils in cancer carcinogenesis and metastasis. J Hematol Oncol. 14:1732021. View Article : Google Scholar
26	Terry RL and Miller SD: Molecular control of monocyte development. Cell Immunol. 291:16–21. 2014. View Article : Google Scholar
27	Miao X, Leng X and Zhang Q: The current state of nanoparticle-induced macrophage polarization and reprogramming research. Int J Mol Sci. 18:3362017. View Article : Google Scholar
28	Biswas SK and Mantovani A: Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm. Nat Immunol. 11:889–896. 2010. View Article : Google Scholar
29	Salmena L, Poliseno L, Tay Y, Kats L and Pandolfi PP: A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language? Cell. 146:353–358. 2011. View Article : Google Scholar
30	Maughan KL, Lutterbie MA and Ham PS: Treatment of breast cancer. Am Fam Physician. 81:1339–1346. 2010.PubMed/NCBI
31	Yu T, Gan S, Zhu Q, Dai D, Li N, Wang H, Chen X, Hou D, Wang Y, Pan Q, et al: Modulation of M2 macrophage polarization by the crosstalk between Stat6 and Trim24. Nat Commun. 10:43532019. View Article : Google Scholar : PubMed/NCBI
32	Ghafouri-Fard S, Abak A, Tavakkoli Avval S, Shoorei H, Taheri M and Samadian M: The impact of non-coding RNAs on macrophage polarization. Biomed Pharmacother. 142:1121122021. View Article : Google Scholar : PubMed/NCBI
33	Zong S, Dai W, Guo X and Wang K: LncRNA-SNHG1 promotes macrophage M2-like polarization and contributes to breast cancer growth and metastasis. Aging (Albany NY). 13:23169–23181. 2021. View Article : Google Scholar : PubMed/NCBI
34	Li H, Jiang T, Li MQ, Zheng XL and Zhao GJ: Transcriptional regulation of macrophages polarization by MicroRNAs. Front Immunol. 9:11752018. View Article : Google Scholar
35	Sánchez-González I, Bobien A, Molnar C, Schmid S, Strotbek M, Boerries M, Busch H and Olayioye MA: miR-149 suppresses breast cancer metastasis by blocking paracrine interactions with macrophages. Cancer Res. 80:1330–1341. 2020. View Article : Google Scholar